press center press release

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) to Ring The Nasdaq Stock Market Opening Bell

Published

ADVISORY, April 01, 2016 (GLOBE NEWSWIRE) --

What: 

Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN), a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Robert Landry, Senior Vice President and Chief Financial Officer, will ring the Opening Bell. 

Where: 

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When: 

Monday, April 4, 2016 – 9:15 a.m. to 9:30 a.m. ET         

Regeneron Media Contact: 

Alexandra Bowie

(914) 847-3407 

alexandra.bowie@regeneron.com

Nasdaq MarketSite: 

Emily Pan

(646) 441-5120 

emily.pan@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Social Media: 

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: 

http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: 

http://instagram.com/nasdaq

For livestream of ceremonies and events visit our YouTube Page: 

http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page at: 

http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit our Tumblr Page: 

http://nasdaq.tumblr.com/

Webcast:

A LiveStream of the Nasdaq Opening Bell will be available at:

https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About Regeneron Pharmaceuticals, Inc. 

Regeneron (Nasdaq:REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

About NASDAQ-100 Index® 

The NASDAQ-100 Index, launched in January 1985, is one of the most widely followed benchmarks in the world. The NASDAQ-100 Index is the basis of the PowerShares QQQ Trust (Nasdaq:QQQ) which aims to provide investment results that, before expenses, correspond with the NASDAQ-100 Index's performance. In addition, options, futures and structured products based on the NASDAQ-100 Index and the PowerShares QQQ Trust trade on various exchanges.

About Nasdaq 

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and nearly 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-

In This Story

NDAQ

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more